Key Dates

Related Announcements

PAR-19-343

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)."

The following changes have been made to reflect NIDA’s participation in this FOA. The changes are in italics.:

Part 1. Overview Information

Components of Participating Organizations

National Institute of General Medical Sciences (NIGMS)
National Institute of Biomedical Imaging and Bioengineering ( NIBIB )
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Human Genome Research Institute ( NHGRI )
National Institute on Aging (NIA)
National Library of Medicine (NLM)
National Institute of Mental Health (NIMH)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.859, 93.286, 93.361, 93.307, 93.172, 93.866, 93.879, 93.279

Part 2. Section I. Funding Opportunity Description

Program Considerations

NIDA supports a broad portfolio of research that encompasses basic, behavioral, epidemiological, health services, prevention, and treatment development research that examines the underlying mechanisms and health effects of substance use and substance use disorders. Interested applicants should review NIDA’s strategic plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan) and funding priorities (https://www.drugabuse.gov/funding) and are highly encouraged to contact program staff listed below to discuss your application prior to submission.

Section II. Award Information

Other Award Budget Information

Salary Support: NIDA will provide K99 salary support up to $90,000 plus fringe benefits per year.

Research Support: NIDA will provide up to $50,000 per year for the K99 phase.

Part 2. Section VII. Agency Contacts

The following contacts have been added:

Scientific/Research Contact(s)

Albert Avila, Ph.D.
Director, Office of Diversity and Health Disparities
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: [email protected]

Peer Review Contact(s)

Dharmendar Rathore, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-6965
Email: [email protected]

Financial/Grants Management Contact(s)

Yinka Abu
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6691
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Albert Avila, Ph.D.
Director, Office of Diversity and Health Disparities
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: [email protected]